The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart dis- ease to cholesterol lowering. JAMA. 1984;251:365 74. 4.4.3. Monitoring in Response to LDL-C Lowering Therapy S4.4.3-1. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce ath- erosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1 45. S4.4.3-2. Benner JS, Tierce JC, Ballantyne CM, et al. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics 2004:22 suppl 3:13 23. S4.4.3-3. Chiavaroli L, Nishi SK, Khan TA, et al. Portfolio dietary pattern and cardiovascular disease: a systematic review and meta-analysis of controlled trials. Prog Cardiovasc Dis. 2018;61:43 53. 4.4.4. Primary Prevention in Other Age Groups 4.4.4.1. Older Adults S4.4.4.1-1. Glynn RJ, Koenig W, Nordestgaard BG, et al. Rosuvastatin for primary prevention in older persons with elevated C-reactive pro- tein and low to average low-density lipoprotein cholesterol lev- els: exploratory analysis of a randomized trial. Ann Intern Med. 2010;152:488 96. w174. S4.4.4.1-2. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive pro- tein. N Engl J Med. 2008;359:2195 207. S4.4.4.1-3. Ridker PM, Lonn E, Paynter NP, et al. Primary prevention with statin therapy in the elderly: new meta-analyses from the con- temporary JUPITER and HOPE-3 randomized trials. Circulation. 2017;135:1979 81. S4.4.4.1-4. Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2021 31. S4.4.4.1-5. Orkaby AR, Gaziano JM, Djousse L, et al. Statins for primary pre- vention of cardiovascular events and mortality in older men. J Am Geriatr Soc. 2017;65:2362 8. S4.4.4.1-6. 